Milken Institute Review | Fixing Generic Drugs With Voluntary Privatized Regulation

Larry Fisher, a former New York Times reporter, quotes Valisure’s CEO, David Light, in the Milken Institute Review, acknowledging our past work and making a case for privatized regulation of generic drugs.

Read the full article titled, "Fixing Generic Drugs With Voluntary Privatized Regulation" here.

Milken Institute Review | Fixing Generic Drugs With Voluntary Privatized Regulation

April 20, 2022

Larry Fisher, a former New York Times reporter, quotes Valisure’s CEO, David Light, in the Milken Institute Review, acknowledging our past work and making a case for privatized regulation of generic drugs.

Read the full article titled, "Fixing Generic Drugs With Voluntary Privatized Regulation" here.

Milken Institute Review | Fixing Generic Drugs With Voluntary Privatized Regulation

Larry Fisher, a former New York Times reporter, quotes Valisure’s CEO, David Light, in the Milken Institute Review, acknowledging our past work and making a case for privatized regulation of generic drugs.

Read the full article titled, "Fixing Generic Drugs With Voluntary Privatized Regulation" here.

Larry Fisher, a former New York Times reporter, quotes Valisure’s CEO, David Light, in the Milken Institute Review, acknowledging our past work and making a case for privatized regulation of generic drugs.

Read the full article titled, "Fixing Generic Drugs With Voluntary Privatized Regulation" here.

SIGN UP FOR THE VALISURE NEWSLETTER 

Sign up to stay updated with Valisure announcements, relevant industry news, company updates, and more. 

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.